← Return to Recovery time after Anastrozole/aromatase inhibitors

Discussion
Comment receiving replies
Profile picture for Rubyslippers @triciaot

@dmr4ever I’m postmenopausal, 68 at diagnosis, and on tamoxifen. The oncologist said I could choose tamoxifen or AI. This came from a highly recognized comprehensive cancer center in 2022.
My understanding of the research is that AIs have a slight, yet statistically significant, better outcome in postmenopausal women. A statistically significant number can be very small, and in this case I felt not a big enough difference to choose an AI.
Although, whether HER2 is positive or negative might affect the outcomes, making an AI a better choice.

Jump to this post


Replies to "@dmr4ever I’m postmenopausal, 68 at diagnosis, and on tamoxifen. The oncologist said I could choose tamoxifen..."

@triciaot
Yes. With a very large sample size/population a small percentage can be referred to as statistically significant. A statistical significance confirms that a result is not random. Which from a practitioner’s perspective is more meaningful than no treatment at all. On an individual level the small statistical probability is not necessarily practical. Researchers perceive patients as a group of thousands. What matters to me is my individual experience with quality of life. For me it is an issue of extending suffering vs actual living. I am so nauseous and fatigued every day that I miss out on my granddaughters’ events, can’t travel. have difficulty with activities of daily living. I am also 68, feel 80 and am not sure dying is the worst thing that can happen to me. I worked for Elsevier, Inc. (the largest medical publisher in the world) and edited drug studies for their MD Consult product. I have read all the studies and am aware of how statistically groundbreaking the results are for the world population. ScienceDirect.com, NIH and similar legitimate sources are my go-to for information. So I am making a well informed decision if I decide to stop the AI.